ArticleFrontiers in public health2025
Analysis of nationwide availability of negotiated drugs in China's National Reimbursement Drug List.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the availability of Price-Negotiated Drugs under China's National Reimbursement Drug List in healthcare institutions and designated retail pharmacies. Methods: This cross-sectional study uses data from the National Health Insurance Service Platform (extracted in September 2025) to evaluate the availability of 383 National Negotiated Drugs in healthcare institutions and retail pharmacies nationwide. According to the World Health Organization (WHO)/Health Action International (HAI) framework, availability was assessed based on the availability rate and allocation rate. Spearman's rank correlation test ( Results: The overall availability of negotiated drugs was low, with mean availability rates of 2.08% in healthcare institutions and 0.13% in designated retail pharmacies. Although drugs were predominantly concentrated in tertiary hospitals, their average availability there remained modest at 9.84%. Substantial provincial disparities were observed in the allocation of tertiary hospitals, with the eastern regions showing relatively higher rates. Drugs added to the formulary earlier and those with higher clinical demand were more available. Spearman's correlation analysis indicated significant associations between drug availability and timing of formulary inclusion ( Conclusion: According to the WHO/HAI standards, the overall availability of negotiated drugs in China remains relatively low, with notable institutional stratification and regional disparities. This finding suggests that policy efforts should focus on strengthening supply incentives and promoting rational drug use. Additionally, policymakers should consider the differences across regions and institutions when advancing drug availability to ensure equitable access to medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.